AI transforming genetic insight into preventive medicine—at clinical scale

Founded: 2019

Valor Investment: Led seed round lead (2021)

Category: Genomics, Precision Medicine, Clinical AI, HealthTech

Why Valor Invested

Valor led Allelica’s seed round in 2021 because we believed polygenic risk scores (PRS) would become a foundational layer of modern medicine, not a niche research tool. Since we invested, Allelica has inked major partnerships with Illumina, Thermofisher, Labcorp, and Invitae, plus acquired major research hospitals such as Mayo Clinic, Stanford, Scripps and Cleveland Clinic as customers. It is now accepted by major insurance.

Before Allelica, healthcare relied on population-level statistics and incomplete genetic signals to assess disease risk. Monogenic testing alone explains only a small fraction of who will actually develop common diseases like coronary artery disease or breast cancer. The missing piece has always been the ability to translate genome-wide risk into something clinically actionable, equitable, and scalable.

Allelica stood out in 2021 as backable AI, because the team was not only advancing PRS science—they were building the clinical software, intelligence layer, workflows, and regulatory foundation required for real-world adoption. Their multi-ancestry approach addressed one of the most critical failures in genomics: biased performance across populations.

What Allelica Does

Allelica is a precision medicine AI that brings polygenic risk scores into routine clinical care, enabling earlier detection, better prevention, and more personalized treatment decisions.

Using a patient’s entire genome, Allelica stratifies individuals by inherited risk across common diseases—complementing traditional risk factors and monogenic testing. The result is a clearer, more complete picture of disease risk that clinicians can act on with confidence.

Allelica’s platform supports applications across:

• Cardiology

• Oncology

• Fertility and women’s health

• Neurology

• Pediatrics

• Preventive and primary care

At its core, Allelica transforms complex genomic data into clinically usable insight, making precision medicine accessible beyond elite research settings.

The New Clinical Standard: AbsoluteDx

Allelica has productized its science into AbsoluteDx, a comprehensive clinical genetic test that combines monogenic and polygenic risk assessment in a single solution.

AbsoluteDx captures the crucial interplay between rare pathogenic variants and genome-wide risk—something the traditional standard of care overlooks. Two patients with the same mutation can have very different absolute disease risk; AbsoluteDx reveals that difference.

Key capabilities include:

• Combined monogenic + polygenic risk reporting

• Multi-ancestry PRSs across major disease categories

• NCCN and ACMG guideline-aligned gene coverage

• Single, non-invasive saliva sample

• Disease-specific panels for breast cancer, prostate cancer, and cardiovascular disease

Delivered in partnership with Broad Institute–affiliated CLIA- and CAP-certified laboratories, AbsoluteDx sets a new benchmark for clinical genomics.Who It’s For

Allelica serves healthcare systems and clinicians focused on prevention, early intervention, and personalized care.

Why It Matters

“Genes are not destiny”—but ignoring them is a missed opportunity.

Allelica matters because it:

• Identifies risk earlier: Flags high-risk individuals long before symptoms appear

• Improves equity: Multi-ancestry PRS reduces bias baked into legacy assessment protocols

• Enables prevention: Turns abstract genetic risk into actionable clinical decisions

• Builds trust: Makes risk discussions more concrete and collaborative for patients

For example, CAD PRS identifies ~20% of the population with double the risk of coronary artery disease, and the top 5–7% with risk equivalent to familial hypercholesterolemia—yet far more common and often undetected today.

Valor’s Perspective

Allelica represents the kind of company Valor aims to back early: scientifically rigorous artificial intelligence, a significant scientific moat, ethically grounded, and committed to building infrastructure that changes outcomes at population scale.

By making inherited risk visible—and actionable—Allelica is helping shift medicine from reaction to prevention. We’re proud to have led their seed round and to support the team as they bring precision medicine into everyday clinical practice worldwide.